TCRX - NASDAQ

TScan Therapeutics, Inc.

TCRX·NASDAQ

$1.01

+4.6%

HealthcareBiotechnology

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$61.99M

EPS-1.0000

P/E Ratio-1.01

Earnings Date08/11/2026

tcrx

Net Cash Provided by Investing Activities

Last Annual Value

109.37M

3-Year CAGR

203%

5-Year CAGR

94%

10-Year CAGR

57%

Adjust for Inflation

TScan Therapeutics, Inc. Competitors Analysis of Net Cash Provided by Investing Activities

TCRX · NASDAQ

Company	Net Cash Provided by Investing Activities	CAGR 3Y	CAGR 5Y	CAGR 10Y
TScan Therapeutics, Inc. NASDAQ:TCRX	109.37M	N/A	N/A	N/A
Fortress Biotech, Inc. NASDAQ:FBIO	10.12M	N/A	-24.2%	N/A
Adicet Bio, Inc. NASDAQ:ACET	2.39M	N/A	N/A	N/A
XBiotech Inc. NASDAQ:XBIT	-289.00K	N/A	N/A	N/A
Context Therapeutics Inc. NASDAQ:CNTX	-2.03M	N/A	N/A	N/A
TuHURA Biosciences, Inc. NASDAQ:HURA	-1.34M	N/A	N/A	N/A
Surrozen, Inc. NASDAQ:SRZN	-128.00K	N/A	N/A	N/A
VistaGen Therapeutics, Inc. NASDAQ:VTGN	-13.15M	N/A	N/A	N/A
Agenus Inc. NASDAQ:AGEN	27.00K	-80.0%	N/A	-47.7%
Inovio Pharmaceuticals, Inc. NASDAQ:INO	14.04M	-45.6%	N/A	-1.5%
Nautilus Biotechnology, Inc. NASDAQ:NAUT	35.22M	N/A	N/A	N/A

TScan Therapeutics, Inc. Fair Value Envelope

TCRX · NASDAQ

Our analysis suggests that TCRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.015, this represents a potential HIDDEN relative to our calculated worth for TScan Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.015

Related Guides

Blog Categories

Continue your TCRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.